Abstract
Background This meta-analysis aimed to evaluate the efficacy and safety of Javanica oil emulsion injection (JOI) combined with chemotherapy versus chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). Methods Electronic databases including EMBASE, PUBMED, the Cochrane library, and Chinese Biological Medical disc (CBM) were searched until May 2018. The clinical trials reporting efficacy and immune function of JOI combined with chemotherapy versus chemotherapy in advanced NSCLC were included according to the inclusion and exclusion criteria. Stata 11 and RevMan 5.3 were used for meta-analysis. Results Twenty-four studies involving 2089 cases were included. The results of the meta-analysis showed that there were significant differences in objective response rate (risk ratio (RR) = 1.17; 95% confidence interval (CI): 1.05–1.29; P < 0.05), improvement in Karnofsky Performance Status (standard mean difference (SMD) = 1.59; 95% CI: 1.41–1.77; P < 0.01), incidence of adverse events (RR = 0.78; 95% CI: 0.7–0.87; P < 0.05), percentage changes of CD3+ cells (SMD = 2.0; 95% CI: 1.49–2.50; P < 0.01), CD4+ cells (SMD = 1.55; 95% CI, 1.2–1.9; P < 0.01), natural killer cells (SMD = 1.98; 95% CI: 1.15–2.82; P < 0.01), but not CD8+ (SMD = −1.44; 95% CI: −4.53–1.65; P=0.36), and value of CD4+/CD8+ (SMD = 0.32; 95% CI: 0.28–0.36; P < 0.01) between the JOI combination group and control group. Funnel plot and Begg's and Egger's analysis indicated that there was no significant publication bias (P > 0.05). Conclusions JOI may be effective to improve the efficacy of chemotherapy in advanced NSCLC patients, accompanied with better levels of immune cells.
Highlights
Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%–85% of lung cancer [1]
Electronic databases including EMBASE, PUBMED, the Cochrane library, and Chinese Biological Medical disc (CBM) were searched until May 2018. e clinical trials reporting efficacy and immune function of Javanica oil emulsion injection (JOI) combined with chemotherapy versus chemotherapy in advanced NSCLC were included according to the inclusion and exclusion criteria
Electronic databases including EMBASE, PUBMED, the conference proceedings of the American Society of Clinical Oncology (ASCO), the Cochrane library, and Chinese Biological Medical disc (CBM) were searched until May 2018 to identify clinical trials and/or randomized controlled trials (RCTs) of JOI combined with chemotherapy versus chemotherapy for advanced NSCLC. e search terms were Javanica oil emulsion injection, Javanica injection, Brucea oil injection, non-small-cell lung cancer, NSCLC, immunity, and immune function. e “similar articles” function in PUBMED was used to further identify potential eligible studies
Summary
Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%–85% of lung cancer [1]. It has become one of the most lethal tumors worldwide [1]. New treatment options can significantly improve the prognosis of these patients, chemotherapy still plays an important role in the treatment of advanced disease [4]. E CD3+, CD4+, and CD8+ cell subsets belong to T lymphocytes and play important roles in antitumor immunity [5, 6]. Patients with advanced cancer show reduced immune function, exhibiting imbalance of
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Evidence-based complementary and alternative medicine : eCAM
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
